Business News

Narayana Murthy disappointed after Nandan Nilekani says no wrongdoing in Infosys’ Panaya deal

The former chairperson said many of his questions related to corporate governance in the firm still remain unanswered.

Infosys Co-founder and former Chairperson NR Narayana Murthy on Tuesday said he was disappointed by the answers given by the company’s board to the questions related to corporate governance, NDTV reported.

Murthy’s response came after Infosys cut its growth forecast for 2017-’18 to 5.5%-6.5%. It had earlier predicted a revenue growth of 6.5%-8.5% during the year. The company on Tuesday reported 7% quarter-on-quarter growth in its net profit in July-September period.

Nandan Nilekani, the non-executive chairperson of the information technology giant, on Tuesday declared that the company had found no evidence of wrongdoing in the $200-million acquisition of Israeli automation technology firm Panaya Limited in 2015, reported Mint. Nilekani, however, did not speak about the salary revision for senior executives that Murthy had questioned.

“Let me say that the investigations were regarding the (Panaya) matter and we’ve said that there is no merit in the allegations of wrongdoing,” Nilekani was quoted as saying. “That’s what we’ve said... I think if you look at the actions of the last 60 days, you would’ve seen that what needed to be done has been done.”

Murthy said he was disappointed that the Inofsys board had not answered his questions with the “transparency it deserves”. In a statement, he added, “I stand by every question on poor governance raised in my speech to Infosys investors dated August 29, 2017. The core question still is how and why the Infosys board approved an unusual and unprecedented severance payment agreement of 1000% [of the standard Infosys employment contracts] to the former CFO, and why the board did not disclose this information proactively and much earlier.” He added that “sadly”, it appeared that people would not “know the truth.”

In the last one-and-a-half years, Murthy has questioned the Infosys board members over poor corporate governance, pay revision for senior executives and the Panaya deal. After former Chief Executive Officer Vishal Sikka quit the company on August 18, the Infosys board had claimed that the “continuous assaults” by Murthy had forced Sikka to leave.

Support our journalism by subscribing to Scroll+ here. We welcome your comments at
Sponsored Content BY 

Following a mountaineer as he reaches the summit of Mount Everest

Accounts from Vikas Dimri’s second attempt reveal the immense fortitude and strength needed to summit the Everest.

Vikas Dimri made a huge attempt last year to climb the Mount Everest. Fate had other plans. Thwarted by unfavourable weather at the last minute, he came so close and yet not close enough to say he was at the top. But that did not deter him. Vikas is back on the Everest trail now, and this time he’s sharing his experiences at every leg of the journey.

The Everest journey began from the Lukla airport, known for its dicey landing conditions. It reminded him of the failed expedition, but he still moved on to Namche Bazaar - the staging point for Everest expeditions - with a positive mind. Vikas let the wisdom of the mountains guide him as he battled doubt and memories of the previous expedition. In his words, the Everest taught him that, “To conquer our personal Everest, we need to drop all our unnecessary baggage, be it physical or mental or even emotional”.

Vikas used a ‘descent for ascent’ approach to acclimatise. In this approach, mountaineers gain altitude during the day, but descend to catch some sleep. Acclimatising to such high altitudes is crucial as the lack of adequate oxygen can cause dizziness, nausea, headache and even muscle death. As Vikas prepared to scale the riskiest part of the climb - the unstable and continuously melting Khumbhu ice fall - he pondered over his journey so far.

His brother’s diagnosis of a heart condition in his youth was a wakeup call for the rather sedentary Vikas, and that is when he started focusing on his health more. For the first time in his life, he began to appreciate the power of nutrition and experimented with different diets and supplements for their health benefits. His quest for better health also motivated him to take up hiking, marathon running, squash and, eventually, a summit of the Everest.

Back in the Himalayas, after a string of sleepless nights, Vikas and his team ascended to Camp 2 (6,500m) as planned, and then descended to Base Camp for the basic luxuries - hot shower, hot lunch and essential supplements. Back up at Camp 2, the weather played spoiler again as a jet stream - a fast-flowing, narrow air current - moved right over the mountain. Wisdom from the mountains helped Vikas maintain perspective as they were required to descend 15km to Pheriche Valley. He accepted that “strength lies not merely in chasing the big dream, but also in...accepting that things could go wrong.”

At Camp 4 (8,000m), famously known as the death zone, Vikas caught a clear glimpse of the summit – his dream standing rather tall in front of him.

It was the 18th of May 2018 and Vikas finally reached the top. The top of his Everest…the top of Mount Everest!

Watch the video below to see actual moments from Vikas’ climb.


Vikas credits his strength to dedication, exercise and a healthy diet. He credits dietary supplements for helping him sustain himself in the inhuman conditions on Mount Everest. On heights like these where the oxygen supply drops to 1/3rd the levels on the ground, the body requires 3 times the regular blood volume to pump the requisite amount of oxygen. He, thus, doesn’t embark on an expedition without double checking his supplements and uses Livogen as an aid to maintain adequate amounts of iron in his blood.

Livogen is proud to have supported Vikas Dimri on his ambitious quest and salutes his spirit. To read more about the benefits of iron, see here. To read Vikas Dimri’s account of his expedition, click here.

This article was produced by the Scroll marketing team on behalf of Livogen and not by the Scroll editorial team.